Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of phellodendrine and salt thereof in preparation of medicines for treating hyperuricemia

A technology of hyperuricemia and cortex, which is applied in the fields of drug combination, food science, and pharmaceutical formulation, etc.

Pending Publication Date: 2021-09-03
SHENYANG MEDICAL COLLEGE
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report on the treatment of hyperuricemia and gout by Phellodendronine and its salts

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of phellodendrine and salt thereof in preparation of medicines for treating hyperuricemia
  • Application of phellodendrine and salt thereof in preparation of medicines for treating hyperuricemia
  • Application of phellodendrine and salt thereof in preparation of medicines for treating hyperuricemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Embodiment 1. The present invention inhibits the activity of xanthine oxidase in vitro and reduces the research of uric acid generation

[0020] Activity test: Precisely weigh cortexine hydrochloride and dissolve it with DMSO. The total reaction system was 200 μL. During the reaction, 2 μL of cortex base solution (DMSO was added to the blank group), 158 μL of buffer solution with pH 7.4, 20 μL of nitrogen blue tetrazolium solution (7.5 mM) and 20 μL of enzyme solution ( 5.4U / L) 10μL, incubate at 37°C for 3min, add hypoxanthine solution (10nM) 10μL to start the reaction, immediately measure continuously at 37°C, 560nm for 3min, and record the reaction rate. The ratio of the reaction rate of the experimental group to the reaction rate of the blank group was used as the inhibition rate of the enzyme activity.

[0021] Result: the present invention has obvious inhibitory action to xanthine oxidase in vitro (see figure 1 ), wherein the inhibitory rate of phellodine hydroch...

Embodiment 2

[0022] Embodiment 2. The present invention reduces the research of uric acid level in mice

[0023] Experimental animals: purchased from Liaoning Changsheng Biotechnology Co., Ltd.

[0024] Drugs and health care products for testing: an appropriate amount of Phellodendronine hydrochloride, dissolved in DMSO, and made into a suspension with 2.5% CMC-Na.

[0025] Grouping and administration: 60 (20-25g) of Kunming mice were randomly divided into blank group, model group, low-dose group of Phellodendronine hydrochloride (100mg / kg), middle-dose group of Phellodendronine hydrochloride (200mg / kg), Phellodendronine hydrochloride high-dose group (400mg / kg), 12 in every group. Adopt hypoxanthine potassium in combination with hypoxanthine to make a model, (hypoxanthine 300mg / kg / d, oxonate potassium 500mg / kg / d, intragastric administration), give test drug and health product (model) by intragastric administration The rats in the group were given normal saline) 1 hour later, and then giv...

Embodiment 3

[0031] Embodiment 3. The present invention reduces the research of uric acid level in rat body

[0032] Experimental animals: purchased from Liaoning Changsheng Biotechnology Co., Ltd.

[0033] Drugs and health care products for testing: an appropriate amount of Phellodendronine hydrochloride, dissolved in DMSO, and made into a suspension with 2.5% CMC-Na.

[0034] Grouping and administration: 50 SD rats (200-220g), were randomly divided into blank group, model group, low-dose group of Phellodendron hydrochloride (100mg / kg), middle-dose group of Phellodendron hydrochloride (200mg / kg), hydrochloric acid Phellodendron high-dose group (400mg / kg), 10 rats in each group. Using potassium oxonate combined with hypoxanthine to establish a model, (hypoxanthine 300mg / kg / d intraperitoneal injection, potassium oxonate 300mg / kg / d, intragastric administration), and give test drugs and health care products by intragastric administration (The model group was given physiological saline) 1 ho...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of phellodendrine and a salt thereof in preparation of medicines and health-care foods for treating hyperuricemia. The phellodendrine salt can be a pharmaceutically acceptable salt form of phellodendrine, including but not limited to hydrochloride, sulfate and the like. The phellodendrine or the salt thereof is taken, other active ingredients are added or not added, pharmaceutic adjuvants are added or not added, and various pharmaceutic preparations or health-care products are prepared according to a conventional method. In-vitro experiments and animal experiments prove that the phellodendrine and the salt thereof have the effects of inhibiting xanthine oxidase and reducing uric acid generation, can be used for treating hyperuricemia and gout, and are a new drug or health food with good curative effect and small side effect.

Description

technical field [0001] The invention relates to the field of medicine and health food inventions, in particular to the application of Phellodendronine and its salts in the preparation of medicines and health care products for treating hyperuricemia. Background technique [0002] Under a normal purine diet, if the blood uric acid level on an empty stomach is higher than 420 μmol / L for men and higher than 360 μmol / L for women twice on different days, it is called hyperuricemia. With the increase of blood uric acid level, tiny crystals of sodium urate in the supersaturated state precipitate out and deposit in tissues or organs such as joints, synovium, tendon, kidney and connective tissue, thereby causing gout. The continuous increase of uric acid level can form gout stones, causing acute and chronic inflammation and tissue damage, followed by multi-system damage such as arthritis, urinary tract stones and kidney diseases. At present, hyperuricemia has become the second larges...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4375A61P19/06A23L33/10
CPCA61K31/4375A61P19/06A23L33/10
Inventor 房丽娜苏新曲健源王婧芸陈光亮郝楠
Owner SHENYANG MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com